Indaptus Therapeutics posts third quarter net loss of $2.98 per share
I'm PortAI, I can summarize articles.
Indaptus Therapeutics Inc. reported a net loss of $2.98 per share for Q3 2025, with R&D expenses of approximately $1.5 million, up from $1.4 million in Q3 2024. The company used $11.6 million in operating activities in the first nine months of 2025, compared to $8.9 million in 2024. Cash reserves totaled $5.8 million as of September 30, 2025, expected to last into Q1 2026. The company completed a Phase 1 trial cohort with promising results, with three out of six participants achieving stable disease.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments